^
Association details:
| Biomarker: | No biomarker |
|---|---|
| Cancer: | Marginal Zone Lymphoma |
| Drug: | Gazyva (obinutuzumab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Excerpt:
Marginal Zone Lymphoma: Second-line and Subsequent Therapy…Preferred regimens…Bendamustine + obinutuzumab (not recommended if treated with prior bendamustine)
Secondary therapy:
bendamustine
